Malta - angļu - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - moxifloxacin - film-coated tablet - moxifloxacin 400 mg - antibacterials for systemic use

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - moxifloxacin hydrochloride monohydrate -

Malta - angļu - Medicines Authority

anfarm hellas s.a. 4 achaias str. & trizinias 14564 kifissia, attiki, greece - moxifloxacin hydrochloride - solution for infusion - moxifloxacin hydrochloride 400/250 mg/ml - antibacterials for systemic use

Kanāda - angļu - Health Canada

pharmascience inc - moxifloxacin (moxifloxacin hydrochloride) - tablet - 400mg - moxifloxacin (moxifloxacin hydrochloride) 400mg - quinolones

Kanāda - angļu - Health Canada

jamp pharma corporation - moxifloxacin (moxifloxacin hydrochloride) - tablet - 400mg - moxifloxacin (moxifloxacin hydrochloride) 400mg - quinolones

Kanāda - angļu - Health Canada

jamp pharma corporation - moxifloxacin (moxifloxacin hydrochloride) - tablet - 400mg - moxifloxacin (moxifloxacin hydrochloride) 400mg - quinolones

Kanāda - angļu - Health Canada

jamp pharma corporation - moxifloxacin (moxifloxacin hydrochloride) - solution - 0.5% - moxifloxacin (moxifloxacin hydrochloride) 0.5% - antibacterials

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

a-s medication solutions - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin tablets are indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae [see clinical studies (14.3) ]. mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. moxifloxacin tablets are indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin-susceptible staphylococcus aureus or streptococcus pyogenes [see clinical studies (14.4) ].  moxifloxacin tablets are indicated in adult patients f

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

a-s medication solutions - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin tablets are indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae [see clinical studies (14.3) ]. mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. moxifloxacin tablets are indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin-susceptible staphylococcus aureus or streptococcus pyogenes [see clinical studies (14.4) ].  moxifloxacin tablets are indicated in adult patients f

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin tablets are indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae [see clinical studies (14.3) ]. mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. moxifloxacin tablets are indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin-susceptible staphylococcus aureus or streptococcus pyogenes [see clinical studies (14.4) ].  moxifloxacin tablets are indicated in adult patients f